UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
WASHINGTON, D.C. 20549
___________
FORM 8-K
CURRENT
REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE
SECURITIES EXCHANGE ACT OF 1934
Date of
Report (Date of Earliest Event Reported): December 10, 2011
GERON CORPORATION
(Exact name of registrant as
specified in its charter)
| Delaware |
0-20859 |
75-2287752 |
| (State or other
jurisdiction |
(Commission File
Number) |
(IRS Employer |
| of incorporation) |
|
Identification
No.) |
230 CONSTITUTION DRIVE
MENLO
PARK, CALIFORNIA 94025
(Address of principal executive
offices, including zip code)
(650)
473-7700
(Registrant's telephone number, including area code)
N/A
(Former name or former address, if
changed since last report)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
| [ ] |
|
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR
230.425) |
| |
|
|
| [ ] |
|
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
|
| [ ] |
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b)) |
| |
|
|
| [ ] |
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c)) |
| Item 5.02 |
|
Departure of Directors or Certain
Officers; Election of Directors; Appointment of Certain Officers;
Compensatory Arrangements of Certain
Officers. |
Compensatory Arrangements
of Certain Officers
On December 10, 2011, the Compensation Committee of the Board of
Directors of Geron Corporation (the “Company”) approved cash bonuses for 2011
for the following named executive officers of the Company, which bonuses were paid on December 23, 2011:
|
2011 |
|
Cash |
| Name
and Position |
Bonus |
| |
|
|
|
|
| David L.
Greenwood |
|
$ |
235,800 |
|
| President and Chief Financial
Officer |
|
|
|
|
| Stephen
M. Kelsey, M.D., F.R.C.P., F.R.C.Path. |
|
$ |
156,600 |
|
| Executive Vice President, Head
of R&D, Chief Medical Officer |
|
|
|
|
| Melissa
Kelly Behrs |
|
$ |
107,500 |
|
| Senior Vice President,
Strategic Portfolio Management |
|
|
|
|
| Jane S.
Lebkowski, Ph.D. |
|
$ |
107,200 |
|
| Senior Vice President and Chief
Scientific Officer |
|
|
|
|
SIGNATURE
Pursuant to the requirements of the
Securities Exchange Act of 1934, the registrant has duly caused this report to
be signed on its behalf by the undersigned hereunto duly
authorized.
| |
GERON CORPORATION |
| |
|
| Date: December 23,
2011 |
By: |
/s/ Olivia
Bloom |
|
| |
Name: |
|
|
Olivia K. Bloom |
| |
Title: |
|
|
Vice President, Chief
Accounting Officer |